Targeting senescent cells in the retina with a BCL-xL inhibitor shows promise as a durable treatment for diabetic macular edema, potentially offering long-term visual function improvements.
At JPM, Verve details plot to take genome editing mainstream
SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of
January 10, 2024